Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003702 · ClinicalTrials.gov registry record · Phase 3
Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia
A Phase 3 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
NCT00003702: Completed Phase 3 study, sponsored by Gynecologic Oncology Group.
NCT00003702 is a Phase 3 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 240 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003702, a Phase 3 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
Study Summary
Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate is more effective than dactinomycin in treating patients with gestational trophoblastic neoplasia.
Primary Outcome
Primary outcome is measured as a difference in proportion responding between treatment arms and evaluated using a chi square test. A complete response was defined as a normal hCG sustained over four weekly measurements.
Interventions
- DRUG Methotrexate
- BIOLOGICAL Dactinomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 1999-06 |
| Phase | Phase 3 |
What the finished NCT00003702 record still lists
NCT00003702 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 2 interventions - of which Methotrexate is the first listed.
NCT00003702 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003702 about?
NCT00003702 is a clinical study titled "Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia". Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whethe...
What is the current status of trial NCT00003702?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 1999-06.
What interventions are being tested in trial NCT00003702?
The interventions under investigation include: Methotrexate (DRUG), Dactinomycin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003702?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003702's enrollment target sits among peer trials
240 1273rd of 2000 higher than 710 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia